The study established that AOD9604 mediates its fat-reducing effects through 3-AR upregulation and ACC inhibition, independent of the insulin-like growth factor (IGF-1) axis, which distinguishes its mechanism from full-length hGH
GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and liraglutide (Victoza, Saxenda) work throughout multiple brain regions to reduce appetite and support weight loss
It is the proposed source of any energy-expenditure and fat-oxidation advantage, and it is the mechanistic hook behind the recomposition interest
Based on Phase 2 trial data, retatrutide has demonstrated a number of potential benefits
The results, which were published in the Lancet on Thursday, are very encouraging for the safety and efficacy of orforglipron in people with type 2 diabetes, says Daniel Drucker, an endocrinologist at the University of Toronto, adding that he is awaiting further clinical trial results of the drug in people with obesity
Pharmaceutical companies typically price medications to recoup these development costs plus generate profit during the patent protection period
.png)
